299 related articles for article (PubMed ID: 23465405)
21. Diagnosing lysosomal storage disorders: mucopolysaccharidosis type I.
Johnson BA; Dajnoki A; Bodamer OA
Curr Protoc Hum Genet; 2015 Jan; 84():17.17.1-17.17.8. PubMed ID: 25599668
[TBL] [Abstract][Full Text] [Related]
22. Digital microfluidic platform for multiplexing enzyme assays: implications for lysosomal storage disease screening in newborns.
Sista RS; Eckhardt AE; Wang T; Graham C; Rouse JL; Norton SM; Srinivasan V; Pollack MG; Tolun AA; Bali D; Millington DS; Pamula VK
Clin Chem; 2011 Oct; 57(10):1444-51. PubMed ID: 21859904
[TBL] [Abstract][Full Text] [Related]
23. Simplified newborn screening protocol for lysosomal storage disorders.
Metz TF; Mechtler TP; Orsini JJ; Martin M; Shushan B; Herman JL; Ratschmann R; Item CB; Streubel B; Herkner KR; Kasper DC
Clin Chem; 2011 Sep; 57(9):1286-94. PubMed ID: 21771947
[TBL] [Abstract][Full Text] [Related]
24. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis I.
Blanchard S; Sadilek M; Scott CR; Turecek F; Gelb MH
Clin Chem; 2008 Dec; 54(12):2067-70. PubMed ID: 19042989
[TBL] [Abstract][Full Text] [Related]
25. A pilot newborn screening program for Mucopolysaccharidosis type I in Taiwan.
Lin SP; Lin HY; Wang TJ; Chang CY; Lin CH; Huang SF; Tsai CC; Liu HL; Keutzer J; Chuang CK
Orphanet J Rare Dis; 2013 Sep; 8():147. PubMed ID: 24053568
[TBL] [Abstract][Full Text] [Related]
26. Evaluation, in a highly specialised enzyme laboratory, of a digital microfluidics platform for rapid assessment of lysosomal enzyme activity in dried blood spots.
Hirachan R; Horman A; Burke D; Heales S
JIMD Rep; 2024 Mar; 65(2):124-131. PubMed ID: 38444576
[TBL] [Abstract][Full Text] [Related]
27. Mass Spectrometry but Not Fluorimetry Distinguishes Affected and Pseudodeficiency Patients in Newborn Screening for Pompe Disease.
Liao HC; Chan MJ; Yang CF; Chiang CC; Niu DM; Huang CK; Gelb MH
Clin Chem; 2017 Jul; 63(7):1271-1277. PubMed ID: 28450385
[TBL] [Abstract][Full Text] [Related]
28. Newborn Screening for 6 Lysosomal Storage Disorders in China.
Chang S; Zhan X; Liu Y; Song H; Gong Z; Han L; Maegawa GHB; Gu X; Zhang H
JAMA Netw Open; 2024 May; 7(5):e2410754. PubMed ID: 38739391
[TBL] [Abstract][Full Text] [Related]
29. Newborn Screening for Lysosomal Storage Disorders in Illinois: The Initial 15-Month Experience.
Burton BK; Charrow J; Hoganson GE; Waggoner D; Tinkle B; Braddock SR; Schneider M; Grange DK; Nash C; Shryock H; Barnett R; Shao R; Basheeruddin K; Dizikes G
J Pediatr; 2017 Nov; 190():130-135. PubMed ID: 28728811
[TBL] [Abstract][Full Text] [Related]
30. The North Carolina Experience with Mucopolysaccharidosis Type I Newborn Screening.
Taylor JL; Clinard K; Powell CM; Rehder C; Young SP; Bali D; Beckloff SE; Gehtland LM; Kemper AR; Lee S; Millington D; Patel HS; Shone SM; Woodell C; Zimmerman SJ; Bailey DB; Muenzer J
J Pediatr; 2019 Aug; 211():193-200.e2. PubMed ID: 31133280
[TBL] [Abstract][Full Text] [Related]
31. Diagnosing lysosomal storage diseases in a Brazilian non-newborn population by tandem mass spectrometry.
Brand GD; Matos HC; Cruz GC; Fontes Ndo C; Buzzi M; Brum JM
Clinics (Sao Paulo); 2013 Nov; 68(11):1469-73. PubMed ID: 24270961
[TBL] [Abstract][Full Text] [Related]
32. Diagnosing lysosomal storage disorders: Fabry disease.
Bodamer OA; Johnson B; Dajnoki A
Curr Protoc Hum Genet; 2013; Chapter 17():Unit17.13. PubMed ID: 23595598
[TBL] [Abstract][Full Text] [Related]
33. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria.
Mechtler TP; Stary S; Metz TF; De Jesús VR; Greber-Platzer S; Pollak A; Herkner KR; Streubel B; Kasper DC
Lancet; 2012 Jan; 379(9813):335-41. PubMed ID: 22133539
[TBL] [Abstract][Full Text] [Related]
34. Screening of lysosomal storage disorders: application of the online trapping-and-cleanup liquid chromatography/mass spectrometry method for mucopolysaccharidosis I.
Ombrone D; Malvagia S; Funghini S; Giocaliere E; Della Bona ML; Forni G; De Luca A; Villanelli F; Casetta B; Guerrini R; la Marca G
Eur J Mass Spectrom (Chichester); 2013; 19(6):497-503. PubMed ID: 24378468
[TBL] [Abstract][Full Text] [Related]
35. Precision newborn screening for lysosomal disorders.
Minter Baerg MM; Stoway SD; Hart J; Mott L; Peck DS; Nett SL; Eckerman JS; Lacey JM; Turgeon CT; Gavrilov D; Oglesbee D; Raymond K; Tortorelli S; Matern D; Mørkrid L; Rinaldo P
Genet Med; 2018 Aug; 20(8):847-854. PubMed ID: 29120458
[TBL] [Abstract][Full Text] [Related]
36. Newborn screening for six lysosomal storage disorders in a cohort of Mexican patients: Three-year findings from a screening program in a closed Mexican health system.
Navarrete-Martínez JI; Limón-Rojas AE; Gaytán-García MJ; Reyna-Figueroa J; Wakida-Kusunoki G; Delgado-Calvillo MDR; Cantú-Reyna C; Cruz-Camino H; Cervantes-Barragán DE
Mol Genet Metab; 2017 May; 121(1):16-21. PubMed ID: 28302345
[TBL] [Abstract][Full Text] [Related]
37. Algorithm for Pompe disease newborn screening: results from the Taiwan screening program.
Chiang SC; Hwu WL; Lee NC; Hsu LW; Chien YH
Mol Genet Metab; 2012 Jul; 106(3):281-6. PubMed ID: 22578805
[TBL] [Abstract][Full Text] [Related]
38. Multiplex newborn screening for Pompe, Fabry, Hunter, Gaucher, and Hurler diseases using a digital microfluidic platform.
Sista RS; Wang T; Wu N; Graham C; Eckhardt A; Winger T; Srinivasan V; Bali D; Millington DS; Pamula VK
Clin Chim Acta; 2013 Sep; 424():12-8. PubMed ID: 23660237
[TBL] [Abstract][Full Text] [Related]
39. Reference values for lysosomal enzymes activities using dried blood spots samples - a Brazilian experience.
Müller KB; Rodrigues MD; Pereira VG; Martins AM; D'Almeida V
Diagn Pathol; 2010 Sep; 5():65. PubMed ID: 20920262
[TBL] [Abstract][Full Text] [Related]
40. Tandem mass spectrometry-based multiplex assays for α-mannosidosis and fucosidosis.
Kumar AB; Hong X; Yi F; Wood T; Gelb MH
Mol Genet Metab; 2019 Jul; 127(3):207-211. PubMed ID: 31235216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
